Defining cancer risk in dermatomyositis. Part I

Vishal Madan, H. Chinoy, C. E M Griffiths, R. G. Cooper

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Summary The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion-body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle-specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two-part review series, we examine the evidence for the existence of cancer-associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM. © 2009 British Association of Dermatologists.
    Original languageEnglish
    Pages (from-to)451-455
    Number of pages4
    JournalClinical and Experimental Dermatology
    Volume34
    Issue number4
    DOIs
    Publication statusPublished - Jun 2009

    Keywords

    • POPULATION-BASED COHORT
    • POLYMYOSITIS-DERMATOMYOSITIS
    • PREDICTIVE SIGNS
    • MALIGNANCY
    • ASSOCIATION
    • VASCULITIS
    • FREQUENCY
    • MYOSITIS

    Fingerprint

    Dive into the research topics of 'Defining cancer risk in dermatomyositis. Part I'. Together they form a unique fingerprint.

    Cite this